首页 > 最新文献

JCO precision oncology最新文献

英文 中文
Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib. 接受 Talazoparib 治疗的 BRCA1/2 基因突变乳腺癌患者体内 [18F]-Fluorthanatrace 聚(ADP-核糖)聚合酶正电子发射断层扫描的药效学活性。
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/PO.24.00303
Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Yap, Jennifer K Litton

Purpose: We tested the ability of [18F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib.

Methods: Seven patients with germline BRCA1/2 pathogenic variants underwent [18F]FTT PET-computed tomography scanning at baseline, and five underwent repeat scanning 14 days after talazoparib initiation. Maximum uptake on PET was quantified in the primary tumor, involved nodes, contralateral pectoralis muscle, and lumbar vertebra body level 3, and compared between the two time points.

Results: Blocking of [18F]FTT was observed on the second scan. Potentially strong but nonsignificant correlations were found between changes in tumor volume (on ultrasound at 1 month v baseline) and percentage changes in tumor-to-muscle uptake ratio at 14 days from baseline (Spearman rank correlation coefficient r = 1; P = .083); and between the highest-grade hematologic toxicity and baseline bone marrow-to-muscle (B/M) uptake ratio (r = 0.72; P = .068) and percentage change in B/M ratio at 14 days from baseline (r = 0.87; P = .058).

Conclusion: We conclude that [18F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [18F]FTT uptake can predict response to PARPi and whether uptake of [18F]FTT in bone marrow may be an early predictor of hematologic toxicity.

目的:我们测试了聚(ADP-核糖)聚合酶(PARP)-1抑制剂的放射性标记类似物--[18F]氟散那曲酶(FTT)在接受PARP抑制剂(PARPi)talazoparib治疗的新诊断原发性乳腺癌患者的正电子发射断层扫描(PET)上显示靶参与的能力:方法:七名具有种系BRCA1/2致病变异的患者在基线时接受了[18F]FTT PET计算机断层扫描,其中五名患者在开始使用talazoparib 14天后接受了重复扫描。对原发肿瘤、受累结节、对侧胸肌和腰椎体第 3 层 PET 的最大摄取量进行量化,并在两个时间点之间进行比较:结果:第二次扫描发现[18F]FTT受阻。肿瘤体积的变化(1 个月后的超声波与基线相比)与 14 天后肿瘤与肌肉摄取比的百分比变化(斯皮尔曼秩相关系数 r = 1;P = .083);以及最高级别血液学毒性与基线骨髓-肌肉(B/M)摄取比之间的相关系数(r = 0.72;P = .068)和从基线开始 14 天后 B/M 比的百分比变化之间的相关系数(r = 0.87;P = .058):我们得出结论:[18F]FTT 可以成像 PARPi 的靶点参与情况,但还需要进行更大规模的研究,以确定[18F]FTT 摄取量是否可以预测对 PARPi 的反应,以及骨髓中的[18F]FTT 摄取量是否可以作为血液毒性的早期预测指标。
{"title":"Pharmacodynamic Activity of [<sup>18</sup>F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With <i>BRCA1/2</i>-Mutated Breast Cancer Receiving Talazoparib.","authors":"Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Yap, Jennifer K Litton","doi":"10.1200/PO.24.00303","DOIUrl":"10.1200/PO.24.00303","url":null,"abstract":"<p><strong>Purpose: </strong>We tested the ability of [<sup>18</sup>F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib.</p><p><strong>Methods: </strong>Seven patients with germline <i>BRCA1/2</i> pathogenic variants underwent [<sup>18</sup>F]FTT PET-computed tomography scanning at baseline, and five underwent repeat scanning 14 days after talazoparib initiation. Maximum uptake on PET was quantified in the primary tumor, involved nodes, contralateral pectoralis muscle, and lumbar vertebra body level 3, and compared between the two time points.</p><p><strong>Results: </strong>Blocking of [<sup>18</sup>F]FTT was observed on the second scan. Potentially strong but nonsignificant correlations were found between changes in tumor volume (on ultrasound at 1 month <i>v</i> baseline) and percentage changes in tumor-to-muscle uptake ratio at 14 days from baseline (Spearman rank correlation coefficient <i>r</i> = 1; <i>P</i> = .083); and between the highest-grade hematologic toxicity and baseline bone marrow-to-muscle (B/M) uptake ratio (<i>r</i> = 0.72; <i>P</i> = .068) and percentage change in B/M ratio at 14 days from baseline (<i>r</i> = 0.87; <i>P</i> = .058).</p><p><strong>Conclusion: </strong>We conclude that [<sup>18</sup>F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [<sup>18</sup>F]FTT uptake can predict response to PARPi and whether uptake of [<sup>18</sup>F]FTT in bone marrow may be an early predictor of hematologic toxicity.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"I Just Assumed This Was Already Being Done": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology. "我只是假设这已经在做了":加拿大患者对加强精准肿瘤学数据共享的偏好。
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/PO.24.00184
Samantha Pollard, Morgan Ehman, Anna Hermansen, Deirdre Weymann, Emanuel Krebs, Cheryl Ho, Howard J Lim, Steven Jones, Yvonne Bombard, Timothy P Hanna, Chiquita Hessels, Holly Longstaff, Robert Cook-Deegan, Tania Bubela, Dean A Regier

Purpose: In Canada, health data are siloed, slowing bioinnovation and evidence generation for personalized cancer care. Secured data-sharing platforms (SDSPs) can enable data analysis across silos through rapid concatenation across trial and real-world settings and timely researcher access. To motivate patient participation and trust in research, it is critical to ensure that SDSP design and oversight align with patients' values and address their concerns. We sought to qualitatively characterize patient preferences for the design of a pan-Canadian SDSP.

Methods: Between January 2022 and July 2023, we conducted pan-Canadian virtual focus groups with individuals who had a personal history of cancer. Following each focus group, participants were invited to provide feedback on early-phase analysis results via a member-checking survey. Three trained qualitative researchers analyzed data using thematic analysis.

Results: Twenty-eight individuals participated across five focus groups. Four focus groups were conducted in English and one in French. Thematic analysis generated two major and five minor themes. Analytic themes spanned personal and population implications of data sharing and willingness to manage perceived risks. Participants were supportive of increasing access to health data for precision oncology research, while voicing concerns about unintended data use, reidentification, and inequitable access to costly therapeutics. To mitigate perceived risks, participants highlighted the value of data access oversight and governance and informational transparency.

Conclusion: Strategies for secured data sharing should anticipate and mitigate the risks that patients perceive. Participants supported enhancing timely research capability while ensuring safeguards to protect patient autonomy and privacy. Our study informs the development of data-governance and data-sharing frameworks that integrate real-world and trial data, informed by evidence from direct patient input.

目的:在加拿大,健康数据各自为政,减缓了个性化癌症治疗的生物创新和证据生成。安全的数据共享平台(SDSP)可以通过快速整合试验和真实世界环境中的数据,以及研究人员的及时访问,实现跨孤岛的数据分析。为了激励患者参与研究并提高他们对研究的信任,确保 SDSP 的设计和监督符合患者的价值观并解决他们关心的问题至关重要。我们试图定性分析患者对泛加拿大 SDSP 设计的偏好:2022 年 1 月至 2023 年 7 月期间,我们与有个人癌症病史的个人开展了泛加拿大虚拟焦点小组。每次焦点小组讨论结束后,我们都会邀请参与者通过成员检查调查对早期阶段的分析结果提供反馈意见。三位训练有素的定性研究人员采用主题分析法对数据进行了分析:共有 28 人参加了五个焦点小组。四个焦点小组以英语进行,一个以法语进行。专题分析产生了两个主要专题和五个次要专题。分析主题涉及数据共享对个人和群体的影响,以及管理感知风险的意愿。参与者支持为精准肿瘤学研究提供更多的健康数据,同时也表达了对意外数据使用、重新识别和不公平获取昂贵治疗药物的担忧。为降低预期风险,与会者强调了数据访问监督和管理以及信息透明度的价值:结论:安全的数据共享策略应预见并降低患者感知到的风险。与会者支持在确保保护患者自主权和隐私的同时提高及时研究能力。我们的研究为制定数据管理和数据共享框架提供了信息,该框架整合了真实世界和试验数据,并以患者直接输入的证据为依据。
{"title":"\"I Just Assumed This Was Already Being Done\": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology.","authors":"Samantha Pollard, Morgan Ehman, Anna Hermansen, Deirdre Weymann, Emanuel Krebs, Cheryl Ho, Howard J Lim, Steven Jones, Yvonne Bombard, Timothy P Hanna, Chiquita Hessels, Holly Longstaff, Robert Cook-Deegan, Tania Bubela, Dean A Regier","doi":"10.1200/PO.24.00184","DOIUrl":"10.1200/PO.24.00184","url":null,"abstract":"<p><strong>Purpose: </strong>In Canada, health data are siloed, slowing bioinnovation and evidence generation for personalized cancer care. Secured data-sharing platforms (SDSPs) can enable data analysis across silos through rapid concatenation across trial and real-world settings and timely researcher access. To motivate patient participation and trust in research, it is critical to ensure that SDSP design and oversight align with patients' values and address their concerns. We sought to qualitatively characterize patient preferences for the design of a pan-Canadian SDSP.</p><p><strong>Methods: </strong>Between January 2022 and July 2023, we conducted pan-Canadian virtual focus groups with individuals who had a personal history of cancer. Following each focus group, participants were invited to provide feedback on early-phase analysis results via a member-checking survey. Three trained qualitative researchers analyzed data using thematic analysis.</p><p><strong>Results: </strong>Twenty-eight individuals participated across five focus groups. Four focus groups were conducted in English and one in French. Thematic analysis generated two major and five minor themes. Analytic themes spanned personal and population implications of data sharing and willingness to manage perceived risks. Participants were supportive of increasing access to health data for precision oncology research, while voicing concerns about unintended data use, reidentification, and inequitable access to costly therapeutics. To mitigate perceived risks, participants highlighted the value of data access oversight and governance and informational transparency.</p><p><strong>Conclusion: </strong>Strategies for secured data sharing should anticipate and mitigate the risks that patients perceive. Participants supported enhancing timely research capability while ensuring safeguards to protect patient autonomy and privacy. Our study informs the development of data-governance and data-sharing frameworks that integrate real-world and trial data, informed by evidence from direct patient input.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. 前列腺癌患者的 DNA 损伤治疗与同源重组修复基因的致病性改变。
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1200/PO.24.00014
Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Deepak Kilari, Michael Pierro, Bicky Thapa, Abhishek Tripathi, George Mo, Matthew Labriola, Joseph J Park, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Tanya Dorff, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Michael T Schweizer

Purpose: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy.

Methods: Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with BRCA1/2 mutations (cohort A) and those with HRR mutations without direct BRCA complex interaction (cohort B: ATM, CDK12, CHEK1, CHEK2, and FANCL). Outcomes in patients with HRR mutations with direct BRCA complex interaction were also explored (cohort C: RAD51B/C/D, RAD54L2, BARD1, GEN1, PALB2, FANCA, and BRIP1).

Results: One hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%), P < .001. Median clinical/radiographic progression-free survival (crPFS) with PARPi in cohort A was significantly longer than in cohort B: 15.9 versus 8.7 months, P = .005. PSA50 response rate to platinum therapy was higher in cohort A (62%) than in cohort B (32%), P = .024, although crPFS was not significantly different. PSA50 response rate to PARPi and platinum was 40% and 32%, respectively, in cohort C. In multivariable analysis, cohort A had significantly improved overall survival and crPFS compared with cohort B with PARPi but not platinum chemotherapy.

Conclusion: Patients with BRCA1/2-mutated PC had significantly improved outcomes to PARPi but not platinum chemotherapy compared with those with HRR mutations without direct BRCA complex interaction.

目的:针对前列腺癌(PC)和非 BRCA1/2 同源重组修复(HRR)突变男性患者的 DNA 损伤疗法的疗效数据非常有限。我们评估了接受聚(ADP-核糖)聚合酶抑制剂(PARPi)和/或铂类化疗的男性前列腺癌患者的 HRR 变异情况:方法:采用PROMISE联盟的回顾性数据。评估了BRCA1/2突变患者(群组A)与无直接BRCA复合体相互作用的HRR突变患者(群组B:ATM、CDK12、CHEK1、CHEK2和FANCL)之间的临床结果差异。此外,还探讨了具有直接 BRCA 复合体相互作用的 HRR 突变的患者(C 组:RAD51B/C/D、RAD54L2、BARD1、GEN1、PALB2、FANCA 和 BRIP1)的治疗结果:146名患者接受了PARPi治疗(A组:94人,B组:45人,C组:7人),104名患者接受了铂类化疗(A组:48人,B组:44人,C组:10人)。A组对PARPi的PSA50反应率(61%)高于B组(5%),P < .001。A组患者使用PARPi后的临床/放射学无进展生存期(crPFS)中位数明显长于B组:15.9个月对8.7个月,P = .005。A组对铂类疗法的PSA50反应率(62%)高于B组(32%),P = .024,但crPFS无显著差异。在多变量分析中,与接受PARPi化疗但未接受铂金化疗的队列B相比,队列A的总生存期和crPFS显著改善:结论:BRCA1/2基因突变的PC患者与HRR基因突变但无BRCA复合物直接相互作用的患者相比,接受PARPi而非铂类化疗的疗效显著提高。
{"title":"DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.","authors":"Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Deepak Kilari, Michael Pierro, Bicky Thapa, Abhishek Tripathi, George Mo, Matthew Labriola, Joseph J Park, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Tanya Dorff, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Michael T Schweizer","doi":"10.1200/PO.24.00014","DOIUrl":"10.1200/PO.24.00014","url":null,"abstract":"<p><strong>Purpose: </strong>Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-<i>BRCA1/2</i> homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy.</p><p><strong>Methods: </strong>Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with <i>BRCA1</i>/<i>2</i> mutations (cohort A) and those with HRR mutations without direct BRCA complex interaction (cohort B: <i>ATM</i>, <i>CDK12</i>, <i>CHEK1</i>, <i>CHEK2</i>, and <i>FANCL</i>). Outcomes in patients with HRR mutations with direct BRCA complex interaction were also explored (cohort C: <i>RAD51B/C/D</i>, <i>RAD54L2</i>, <i>BARD1</i>, <i>GEN1</i>, <i>PALB2</i>, <i>FANCA</i>, and <i>BRIP1</i>).</p><p><strong>Results: </strong>One hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%), <i>P</i> < .001. Median clinical/radiographic progression-free survival (crPFS) with PARPi in cohort A was significantly longer than in cohort B: 15.9 versus 8.7 months, <i>P</i> = .005. PSA50 response rate to platinum therapy was higher in cohort A (62%) than in cohort B (32%), <i>P</i> = .024, although crPFS was not significantly different. PSA50 response rate to PARPi and platinum was 40% and 32%, respectively, in cohort C. In multivariable analysis, cohort A had significantly improved overall survival and crPFS compared with cohort B with PARPi but not platinum chemotherapy.</p><p><strong>Conclusion: </strong>Patients with <i>BRCA1/2</i>-mutated PC had significantly improved outcomes to PARPi but not platinum chemotherapy compared with those with HRR mutations without direct BRCA complex interaction.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142043913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis. 勘误:转移性未分化多形性肉瘤抗PD-L1阻断治疗的意外持久完全应答:病例报告及宿主和肿瘤生物标志物分析
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO-24-00427
{"title":"Erratum: Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.","authors":"","doi":"10.1200/PO-24-00427","DOIUrl":"https://doi.org/10.1200/PO-24-00427","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. Palbociclib治疗CDK4扩增的软组织肉瘤患者:靶向药物和剖析利用登记研究的结果
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO.24.00219
Scott Schuetze, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Carmen J Calfa, Laura Catherine Farrington, Michael B Livingston, Kristopher Wentzel, Deepti Behl, Yelena Kier, Alissa S Marr, Margaret von Mehren, Joshua Z Press, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, Richard L Schilsky

Purpose: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (CDK4) amplification treated with palbociclib are reported.

Methods: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.

Results: Forty-two patients with CDK4 amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported.

Conclusion: Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification.

目的:靶向药物和分析利用登记处(TAPUR)是一项II期篮子试验,评估市售靶向药物对晚期癌症患者的抗肿瘤活性以及已知为药物靶点的基因组改变。本文报告了一组使用帕博西尼(palbociclib)治疗细胞周期蛋白依赖性激酶4(CDK4)扩增的软组织肉瘤患者的结果:符合条件的患者均患有可测量的疾病、东部合作肿瘤学组表现为0至2级、器官功能正常且无标准治疗方案。主要终点是疾病控制(DC),根据 RECIST v1.1,定义为客观反应(OR)或至少持续 16 周以上的疾病稳定(SD)(SD16+)。疾病控制率的估计值为 90% CI。次要终点包括OR、无进展生存期(PFS)、总生存期(OS)、反应持续时间、SD持续时间和安全性:42例CDK4扩增患者入组。结果:42 例 CDK4 扩增患者入组,其中 1 例无法进行疗效评估。1例部分应答患者和18例SD16+患者的DC和OR观察率分别为46%(90% CI,36至100)和2%(95% CI,结论:Palbociclib符合预后评估的要求:Palbociclib符合预设标准,可宣布对肉瘤和CDK4扩增患者具有抗肿瘤活性信号。
{"title":"Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.","authors":"Scott Schuetze, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Carmen J Calfa, Laura Catherine Farrington, Michael B Livingston, Kristopher Wentzel, Deepti Behl, Yelena Kier, Alissa S Marr, Margaret von Mehren, Joshua Z Press, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, Richard L Schilsky","doi":"10.1200/PO.24.00219","DOIUrl":"10.1200/PO.24.00219","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (<i>CDK4</i>) amplification treated with palbociclib are reported.</p><p><strong>Methods: </strong>Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.</p><p><strong>Results: </strong>Forty-two patients with <i>CDK4</i> amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported.</p><p><strong>Conclusion: </strong>Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and <i>CDK4</i> amplification.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography: Aggressive or Indolent? 前列腺特异性膜抗原正电子发射断层扫描时代的疾病概况解密:侵袭性还是惰性?
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO-24-00377
Peter D Zang, Salvador Jaime-Casas, Wesley Yip
{"title":"Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography: Aggressive or Indolent?","authors":"Peter D Zang, Salvador Jaime-Casas, Wesley Yip","doi":"10.1200/PO-24-00377","DOIUrl":"10.1200/PO-24-00377","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer. 表皮生长因子受体 V834L 和 L858R 基因突变与非小细胞肺癌患者对奥希替尼的反应有关
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO.23.00215
Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon

Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.

奥希替尼可使表皮生长因子受体 V834L 和 L858R 组合型 NSCLC 患者获得临床获益。
{"title":"<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.","authors":"Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon","doi":"10.1200/PO.23.00215","DOIUrl":"10.1200/PO.23.00215","url":null,"abstract":"<p><p>Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Characterization of Metastatic Oncocytoma With Exceptional Response to Treatment: A Case Report. 对治疗有特殊反应的转移性肿瘤细胞瘤的分子特征:病例报告。
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO.24.00188
Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, Dionna Gamble, Daniel R Crooks, Ye Yang, Lindsay Friedman, Antoun Toubaji, Pavlos Msaouel, Jonathan M Hernandez, W Marston Linehan, Mark W Ball

Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma.

对一例罕见的转移性肾肿瘤细胞瘤进行全面的分子鉴定和有效治疗。
{"title":"Molecular Characterization of Metastatic Oncocytoma With Exceptional Response to Treatment: A Case Report.","authors":"Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, Dionna Gamble, Daniel R Crooks, Ye Yang, Lindsay Friedman, Antoun Toubaji, Pavlos Msaouel, Jonathan M Hernandez, W Marston Linehan, Mark W Ball","doi":"10.1200/PO.24.00188","DOIUrl":"10.1200/PO.24.00188","url":null,"abstract":"<p><p>Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism. 应用美国国家综合癌症网络指南进行疑似致病性 TP53 嵌合的诊断和实践挑战。
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO.24.00006
Daniel I Nathan, Tehilla Brander, Julie Gold, Deborah Paul, Paula Klein, Kit Cheng, Johnson M Liu, Bridget K Marcellino

Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.

使用 NCCN 指南区分 TP53 CH 和镶嵌型 LFS 的益处和局限性。
{"title":"Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.","authors":"Daniel I Nathan, Tehilla Brander, Julie Gold, Deborah Paul, Paula Klein, Kit Cheng, Johnson M Liu, Bridget K Marcellino","doi":"10.1200/PO.24.00006","DOIUrl":"10.1200/PO.24.00006","url":null,"abstract":"<p><p>Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports. 新发小细胞肺癌和表皮生长因子受体 20 外显子插入患者的病程和治疗结果:两个病例报告
IF 5.3 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.1200/PO.24.00257
Lodovica Zullo, Elora Castanet, Zineb Maaradji, Maria Rosa Ghigna, Benjamin Bonhomme, Melissa Alamé, Benjamin Besse, Sophie Cousin, Mihaela Aldea

We report the first two cases of EGFR exon20ins SCLC, treated with amivantamab and TKIs.

我们首次报道了两例表皮生长因子受体外显子 20ins SCLC 病例,这两例病例均接受了阿米万他单抗和 TKIs 治疗。
{"title":"Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports.","authors":"Lodovica Zullo, Elora Castanet, Zineb Maaradji, Maria Rosa Ghigna, Benjamin Bonhomme, Melissa Alamé, Benjamin Besse, Sophie Cousin, Mihaela Aldea","doi":"10.1200/PO.24.00257","DOIUrl":"https://doi.org/10.1200/PO.24.00257","url":null,"abstract":"<p><p>We report the first two cases of EGFR exon20ins SCLC, treated with amivantamab and TKIs.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JCO precision oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1